Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Greggi

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialSandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Gynecologic Oncology|April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancerSandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A studyGennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
Tumori|April 22, 2017
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancerDavide Cavaliere, Roberto Cirocchi, Federico Coccolini, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trialRaimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Journal of Gynecologic Oncology|October 20, 2020
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groupsGiorgio Bogani, Giovanni Apolone, Antonino Ditto, et al.
Vaccines|April 23, 2022
Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical DysplasiaGiorgio Bogani, Luca Lalli, Francesco Sopracordevole, et al.
Vaccines|March 30, 2023
Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical ConizationAndrea Giannini, Violante Di Donato, Francesco Sopracordevole, et al.
Gynecologic Oncology|September 7, 2020
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up studyGiorgio Bogani, Violante DI Donato, Francesco Sopracordevole, et al.
Gynecologic Oncology|January 30, 2021
High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomesGiorgio Bogani, Francesco Sopracordevole, Violante Di Donato, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialSandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
Gynecologic Oncology|April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancerSandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A studyGennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
Tumori|April 22, 2017
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancerDavide Cavaliere, Roberto Cirocchi, Federico Coccolini, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trialRaimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Journal of Gynecologic Oncology|October 20, 2020
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groupsGiorgio Bogani, Giovanni Apolone, Antonino Ditto, et al.
Vaccines|April 23, 2022
Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical DysplasiaGiorgio Bogani, Luca Lalli, Francesco Sopracordevole, et al.
Vaccines|March 30, 2023
Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical ConizationAndrea Giannini, Violante Di Donato, Francesco Sopracordevole, et al.
Gynecologic Oncology|September 7, 2020
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up studyGiorgio Bogani, Violante DI Donato, Francesco Sopracordevole, et al.
Gynecologic Oncology|January 30, 2021
High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomesGiorgio Bogani, Francesco Sopracordevole, Violante Di Donato, et al.
Pageof 9